Skip to main content

Compare Stocks

Date Range: 

 Interpace BiosciencesInVivo TherapeuticsVivosArch TherapeuticsObalon Therapeutics
SymbolNASDAQ:IDXGNASDAQ:NVIVOTCMKTS:RDGLOTCMKTS:ARTHNASDAQ:OBLN
Price Information
Current Price$8.10$0.68$0.08$0.13$3.32
52 Week RangeBuyN/AN/ABuyBuy
MarketRank™
Overall Score1.50.70.01.20.5
Analysis Score1.50.00.03.50.0
Community Score2.92.80.02.42.4
Dividend Score0.00.00.00.00.0
Ownership Score2.50.00.00.00.0
Earnings & Valuation Score0.60.60.00.00.0
Analyst Ratings
Consensus RecommendationBuyN/AN/ABuyBuy
Consensus Price Target$8.00N/AN/A$1.38N/A
% Upside from Price Target-1.23% downsideN/AN/A974.22% upsideN/A
Trade Information
Market Cap$33.24 million$23.26 million$26.45 million$30.30 million$33.27 million
Beta1.231.92.880.11-0.69
Average Volume178,9063,840,2543,829,656391,1427,902,003
Sales & Book Value
Annual Revenue$24.08 millionN/A$10,000.00N/A$3.28 million
Price / Sales1.38N/A2,645.08N/A10.14
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$3.41 per share$10.15 per share($0.06) per share($0.01) per share$2.06 per share
Price / Book2.38N/A-1.38N/A1.61
Profitability
Net Income$-26,730,000.00$-11,830,000.00$-1,610,000.00$-4,690,000.00$-23,680,000.00
EPS($5.58)N/AN/AN/AN/A
Trailing P/E RatioN/A0.000.000.00N/A
Forward P/E RatioN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-115.30%N/AN/AN/A-688.07%
Return on Equity (ROE)-251.52%-124.37%N/AN/A-159.14%
Return on Assets (ROA)-37.77%-91.12%-1,120.71%-159.31%-97.30%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio2.01%N/AN/AN/A0.07%
Current Ratio1.62%4.38%0.06%3.32%1.79%
Quick Ratio1.62%4.38%0.06%1.82%1.79%
Ownership Information
Institutional Ownership Percentage17.13%0.48%0.08%0.04%28.00%
Insider Ownership Percentage54.40%0.58%18.50%12.16%8.10%
Miscellaneous
Employees1526172
Shares Outstanding4.10 million34.18 million318.68 million236.72 million10.02 million
Next Earnings Date6/24/2021 (Estimated)N/A6/29/2021 (Estimated)5/18/2021 (Estimated)6/18/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
Obalon Announces First Quarter 2021 Financial ResultsObalon Announces First Quarter 2021 Financial Results
finance.yahoo.com - May 12 at 11:09 AM
Obalon Therapeutics, Inc. Urges Stockholders to IMMEDIATELY Vote FOR All Proposals Related to the Merger with ReShape Lifesciences IncObalon Therapeutics, Inc. Urges Stockholders to IMMEDIATELY Vote FOR All Proposals Related to the Merger with ReShape Lifesciences Inc
dgap.de - May 11 at 11:17 PM
Obalon TherapeuticsInc. (NASDAQ:OBLN) Jumps 30.45% in Recent Session, What Things You Absolutely Need To Know?Obalon TherapeuticsInc. (NASDAQ:OBLN) Jumps 30.45% in Recent Session, What Things You Absolutely Need To Know?
stocksregister.com - May 11 at 1:17 PM
Let’s Jump into the Obalon Therapeutics, Inc. (NASDAQ:OBLN) Stock ForecastLet’s Jump into the Obalon Therapeutics, Inc. (NASDAQ:OBLN) Stock Forecast
marketingsentinel.com - May 10 at 5:12 PM
Obalon Therapeutics, Inc. (NASDAQ:OBLN) Short Interest UpdateObalon Therapeutics, Inc. (NASDAQ:OBLN) Short Interest Update
americanbankingnews.com - May 3 at 1:32 PM
SHAREHOLDER ALERT: WeissLaw LLP Reminds BFTL, OBLN, FI, and BMTC Shareholders About Its Ongoing InvestigationsSHAREHOLDER ALERT: WeissLaw LLP Reminds BFTL, OBLN, FI, and BMTC Shareholders About Its Ongoing Investigations
finance.yahoo.com - April 23 at 7:19 PM
For Obalon Therapeutics Inc. [OBLN], Analyst sees a rise to $3. What next?For Obalon Therapeutics Inc. [OBLN], Analyst sees a rise to $3. What next?
dbtnews.com - April 21 at 2:11 PM
Analysts think Obalon Therapeutics, Inc. (NASDAQ:OBLN) could rise 147.98% from current levelsAnalysts think Obalon Therapeutics, Inc. (NASDAQ:OBLN) could rise 147.98% from current levels
stocksregister.com - April 20 at 12:54 PM
Obalon Therapeutics Inc (OBLN)Obalon Therapeutics Inc (OBLN)
investing.com - April 18 at 10:27 PM
Obalon Announces Fourth Quarter and Full Year 2020 Financial ResultsObalon Announces Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 12 at 7:24 PM
OBLN Stock Price Increases Over 20% Pre-Market: Why It HappenedOBLN Stock Price Increases Over 20% Pre-Market: Why It Happened
pulse2.com - March 10 at 1:09 PM
INVESTIGATION ALERT: Halper Sadeh LLP Investigates VIE, SMTX, NK, OBLN; Shareholders Are Encouraged to Contact the FirmINVESTIGATION ALERT: Halper Sadeh LLP Investigates VIE, SMTX, NK, OBLN; Shareholders Are Encouraged to Contact the Firm
finance.yahoo.com - February 2 at 2:20 PM
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Obalon Therapeutics, Inc. MergerSHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Obalon Therapeutics, Inc. Merger
apnews.com - January 25 at 2:44 PM
Datavisor Global Digital Fraud Trends Report 2021Datavisor Global Digital Fraud Trends Report 2021
globalbankingandfinance.com - January 23 at 2:11 PM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Obalon Therapeutics, Inc. - OBLNSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Obalon Therapeutics, Inc. - OBLN
finance.yahoo.com - January 23 at 9:10 AM
OBALON ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of OBLN and Encourages Investors to Contact the FirmOBALON ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of OBLN and Encourages Investors to Contact the Firm
finance.yahoo.com - January 22 at 6:28 PM
OBALON INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Obalon Therapeutics, Inc. - OBLNOBALON INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Obalon Therapeutics, Inc. - OBLN
businesswire.com - January 22 at 1:28 PM
SHAREHOLDER ALERT: WeissLaw LLP Investigates Obalon Therapeutics, Inc.SHAREHOLDER ALERT: WeissLaw LLP Investigates Obalon Therapeutics, Inc.
finance.yahoo.com - January 21 at 7:16 PM
ROCE Insights For Obalon TherapeuticsROCE Insights For Obalon Therapeutics
finance.yahoo.com - January 21 at 2:15 PM
PFE/BNTX Covid Jab Neutralizes UK Strain, Pura Vida Ups Stake In OCX, Woodcock Is Interim FDA ChiefPFE/BNTX Covid Jab Neutralizes UK Strain, Pura Vida Ups Stake In OCX, Woodcock Is Interim FDA Chief
nasdaq.com - January 21 at 2:48 AM
ReShape and Obalon Merge in All-Stock TransactionReShape and Obalon Merge in All-Stock Transaction
mddionline.com - January 20 at 4:48 PM
Obalon Surges 470% On ReShape Lifesciences Merger AgreementObalon Surges 470% On ReShape Lifesciences Merger Agreement
msn.com - January 20 at 4:48 PM
Return On Capital Employed Overview: Obalon TherapeuticsReturn On Capital Employed Overview: Obalon Therapeutics
finance.yahoo.com - December 7 at 4:42 PM
Why Is It Moving? Analyzing The Upward Movement in Obalon Therapeuticss Stock TodayWhy Is It Moving? Analyzing The Upward Movement in Obalon Therapeutics's Stock Today
finance.yahoo.com - December 7 at 4:42 PM
OBLN Stock: 11 Things to Know About Weight Loss Balloon Play Obalon TherapeuticsOBLN Stock: 11 Things to Know About Weight Loss Balloon Play Obalon Therapeutics
feedproxy.google.com - December 7 at 12:41 PM
DateCompanyBrokerageAction
4/15/2021Interpace BiosciencesHC WainwrightBoost Price Target
10/22/2020Interpace BiosciencesAlliance Global PartnersLower Price Target
4/24/2020Interpace BiosciencesMaxim GroupReiterated Rating
4/15/2020Interpace BiosciencesJanney Montgomery ScottInitiated Coverage
9/26/2019Interpace BiosciencesOppenheimerInitiated Coverage
5/5/2021Arch TherapeuticsDawson JamesInitiated Coverage
8/4/2020Arch TherapeuticsLADENBURG THALM/SH SHReiterated Rating
2/5/2019Arch TherapeuticsRoth CapitalReiterated Rating
2/1/2019Arch TherapeuticsIfs SecuritiesUpgrade
7/24/2019Obalon TherapeuticsNorthland SecuritiesReiterated Rating
4/8/2019Obalon TherapeuticsCanaccord GenuityDowngrade
2/25/2019Obalon TherapeuticsStifel NicolausUpgrade
9/12/2018Obalon TherapeuticsBTIG ResearchReiterated Rating
(Data available from 5/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.